Disease Modifying Therapies for Alzheimer's Disease Targeting Aβ Oligomers: Implications for Therapeutic Mechanisms
Figure 2
Antitoxic activity of 72D9. (a) SH-5YSY cells were exposed to 12.5 μM seed-free A42 with control IgG2b or 72D9 at 37°C for 24 h. Level of LDH released from SH-SY5Y cells treated for 24 h with 12.5 μM A1-42 with control IgG2b or 72D9 at the indicated concentrations (0, 0.5, 1.0, and 1.5 μM). Each value indicates the percent level of LDH released following treatment with incubation mixtures relative to the level of LDH released following treatment with Triton X-100. Each column indicates average SD. The value was determined by one-way ANOVA, followed by Tukey test for post hoc analysis: statistical significance compared with A1-42 alone (). (b) Sections of control 72D9-treated or IgG2b-treated 3xTg-AD mouse brain were analyzed by immunofluorescence imaging of 72D9 (green), polyclonal A11 (red), and DAPI (blue). Inset: representative higher magnification images are shown in the insets of panels (d) and (e).
